Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Allergic Bronchopulmonary Aspergillosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Allergic bronchopulmonary aspergillosis; Asthma
- Focus Therapeutic Use
- Acronyms LIBERTY-ABPA AIRED
- Sponsors Regeneron Pharmaceuticals
- 29 Feb 2024 Status changed from active, no longer recruiting to completed.
- 03 Apr 2023 Study phase changed from Phase 3 to Phase 2. Primary and secondary outcome measures amended.
- 03 Apr 2023 Planned End Date changed from 21 Dec 2023 to 13 Nov 2023.